Alector, Inc.
ALECAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Oct 6, 2026 | Morgan Stanley | $3.00(+51%) | $1.99 | TheFly | |
| Oct 6, 2026 | UBS | Graig Suvannavejh | $1.50(-25%) | $1.99 | StreetInsider |
| May 4, 2026 | Morgan Stanley | $2.00(-18%) | $2.45 | TheFly | |
| Oct 22, 2025 | H.C. Wainwright | $5.00(+56%) | $3.21 | TheFly | |
| Oct 22, 2025 | Mizuho Securities | $1.50(-53%) | $3.21 | TheFly | |
| Nov 19, 2024 | Goldman Sachs | Corinne Jenkins | $4.00(-21%) | $5.08 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Oct 15, 2026 |
| HC Wainwright & Co. | maintain | Buy | Oct 14, 2026 |
| Morgan Stanley | maintain | Underweight | Oct 6, 2026 |
| Cantor Fitzgerald | upgrade | Neutral →Overweight | Apr 15, 2026 |
| BTIG | upgrade | Neutral →Buy | Mar 10, 2026 |
| HC Wainwright & Co. | maintain | Buy | Oct 22, 2025 |
| BTIG | downgrade | Buy →Neutral | Oct 22, 2025 |
| William Blair | downgrade | Outperform →Market Perform | Oct 22, 2025 |
| TD Cowen | downgrade | Buy →Hold | Oct 22, 2025 |
| Cantor Fitzgerald | downgrade | Overweight →Neutral | Oct 22, 2025 |
| BTIG | maintain | Buy | Sep 25, 2025 |
| Mizuho | upgrade | Neutral →Outperform | Jul 28, 2025 |
| HC Wainwright & Co. | maintain | Buy | May 9, 2025 |
| HC Wainwright & Co. | maintain | Buy | Feb 27, 2025 |
| Stifel | downgrade | Buy →Hold | Dec 16, 2024 |
| BTIG | maintain | Buy | Nov 26, 2024 |
| Morgan Stanley | downgrade | Equal Weight →Underweight | Nov 26, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 7, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jun 20, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 9, 2024 |
| HC Wainwright & Co. | maintain | Buy | Feb 28, 2024 |
| Stifel | upgrade | Hold →Buy | Dec 14, 2023 |
| Mizuho | maintain | Buy | Nov 17, 2023 |
| Mizuho | maintain | Buy | Aug 11, 2023 |
| Stifel | maintain | Hold | Aug 8, 2023 |
Earnings History
Next report: Feb 24, 2027 · EPS est. $0.14| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 5, 2026 | $1.11 | $-0.23 | $162.9M | $2.2M |
| Aug 6, 2026 | $-0.21 | $-0.23 | $3.3M | $1.7M |
| May 7, 2026 | $-0.21 | $-0.35 | $1.0M | $9.7M |
| Feb 25, 2026 | $-0.34 | $-0.39 | $6.2M | $2.0M |
| Nov 6, 2025 | $-0.34 | $-0.42 | $3.3M | $1.8M |
| Aug 7, 2025 | $-0.30 | $-0.45 | $7.9M | $2.8M |
| May 8, 2025 | $-0.41 | $-0.44 | $3.7M | $4.3M |
| Feb 26, 2025 | $-0.02 | $-0.61 | $54.2M | $20.4M |
News
Advancing a pipeline built entirely on the Alector Brain Carrier (ABC) blood-brain barrier platform, spanning antibody, enzyme, and siRNA programs, with AL137, Alector's lead ABC-enabled anti-amyloid beta (Aβ) antibody program for Alzheimer's disease (AD), targeting first-in-human dosing in Australia no later than April 2027. Continued progress across AL164 (ABC-enabled Tau siRNA for AD and other tauopathies) and AL062 (ABC-enabled alpha-synuclein siRNA for Parkinson's disease (PD) and Lewy body…
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (“Alector,” Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced the pricing of an underwritten offering of common stock. Alector is selling 36,600,000 shares of common stock. The shares of common stock are being sold at an offering price of $2.05 per share, which represents a premium of approximately 7.3% over the closing …
Alector, Inc. (ALEC) Discusses Strategic Advances in Next Generation Neurodegeneration Therapies and Pipeline Developments Transcript
Alector NASDAQ: ALEC outlined its strategy to advance brain-penetrant therapies for neurodegenerative diseases, highlighting an anti-amyloid beta antibody for Alzheimer's disease and two siRNA programs targeting tau and alpha-synuclein.
Agenda to feature progress for AL137, its lead anti-amyloid beta antibody; AL164, its tau siRNA program; and AL062, its alpha-synuclein siRNA program
Alector grants Genentech exclusive rights to develop and commercialize AL050, an investigational GCase Enzyme Replacement Therapy (ERT) enabled by Alector Brain Carrier (ABC), Alector's proprietary blood-brain barrier delivery platform
Alector (NASDAQ: ALEC - Get Free Report) and Ionis Pharmaceuticals (NASDAQ: IONS - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, earnings, dividends, profitability, valuation and risk. Institutional and Insider Ownership 85.8% of Alector shares are
Alector, Inc. (ALEC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Alector, Inc. (ALEC) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Prepared Remarks Transcript
Alector (NASDAQ: ALEC - Get Free Report) and Sarepta Therapeutics (NASDAQ: SRPT - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations and valuation. Profitability This table compares Alector and Sarepta Therapeutics' net
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases, today announced that management will participate in the following upcoming investor conferences: Cantor Global Healthcare Conference 2026 (New York, New York) Thursday, September 10, 2026, at 2:10 p.m.